Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Renalytix ( (GB:RENX) ) just unveiled an update.
Renalytix plc announced that Chief Executive Officer James McCullough purchased 3,010 American Depositary Shares of the company on 11 February 2026 at an average price of $3.01 per ADS. Following this transaction, McCullough’s total interest amounts to 3,392,596 ordinary shares, representing 0.78% of the company’s issued share capital.
The CEO’s share purchase signals management confidence in Renalytix’s prospects as it scales deployment of its kidneyintelX.dkd prognostic test in the U.S. market. With established Medicare reimbursement and growing real-world data supporting improved diagnosis and treatment rates, the move may reassure investors about the company’s growth trajectory in the kidney disease diagnostics space.
The most recent analyst rating on (GB:RENX) stock is a Sell with a £5.50 price target. To see the full list of analyst forecasts on Renalytix stock, see the GB:RENX Stock Forecast page.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative equity, and ongoing cash burn) and a bearish technical trend (price below key moving averages and negative MACD). Positive corporate updates and oversold signals provide some support, but they do not offset current financial and trend risk.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix plc is an AI-enabled in vitro diagnostics company focused on improving clinical management of kidney disease, particularly diabetic kidney disease. Its flagship test, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic tool for early-stage risk assessment in chronic diabetic kidney disease and is commercially available across select U.S. health systems.
Average Trading Volume: 498,288
Technical Sentiment Signal: Sell
Current Market Cap: £25.35M
For an in-depth examination of RENX stock, go to TipRanks’ Overview page.